Development and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorMatosinhos, Rafaela Cunha-
Autor(es): dc.creatorFrezard, Frederic Jean Georges-
Autor(es): dc.creatorAraújo, Sabrina Mendes Silva-
Autor(es): dc.creatorBarbosa, Andressa Magalhães-
Autor(es): dc.creatorSouza, Isabela Fernanda de-
Autor(es): dc.creatorSouza Filho, José Dias de-
Autor(es): dc.creatorSouza, Jacqueline de-
Autor(es): dc.creatorBahia, Ana Paula Corrêa Oliveira-
Autor(es): dc.creatorIetta, Francesca-
Autor(es): dc.creatorMagnani, Agnese-
Autor(es): dc.creatorGuimarães, Dênia Antunes Saúde-
Data de aceite: dc.date.accessioned2025-08-21T15:12:24Z-
Data de disponibilização: dc.date.available2025-08-21T15:12:24Z-
Data de envio: dc.date.issued2025-01-29-
Data de envio: dc.date.issued2025-01-29-
Data de envio: dc.date.issued2023-
Fonte completa do material: dc.identifierhttps://www.repositorio.ufop.br/handle/123456789/19660-
Fonte completa do material: dc.identifierhttps://doi.org/10.1038/s41598-024-57663-1-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1005824-
Descrição: dc.descriptionGout and hyperuricemia are characterized by high uric acid levels, and their treatment involves medications that have adverse effects. In this study, we evaluated oral liposomal formulations with eremantholide C and goyazensolide as a novel approach to reduce the toxicity associated with these substances while maintaining their anti-hyperuricemic activity. We characterized the formulations and evaluated them based on encapsulation efficiency and stability over 12 months and under simulated physiological environments. We determined the toxicity of the liposomal formulations in Caco-2 cells and the anti-hyperuricemic activity in rats. The formulations exhibited nanometric size, a narrow size distribution, and a negative zeta potential, indicating their stability and uniformity. The efficient encapsulation of the sesquiterpene lactones within the liposomes emphasizes their potential for sustained release and therapeutic efficacy. Stability evaluation revealed a small decrease in the eremantholide C concentration and a remarkable stability in the goyazensolide concentration. In Caco-2 cells, the liposomes did not exert toxicity, but did exhibit an antiproliferative effect. In vivo assays demonstrated that the liposomes reduced serum uric acid levels. Our study represents an advancement in gout and hyperuricemia treatment. The liposomal formulations effectively reduced the toxicity associated with the sesquiterpene lactones while maintaining their therapeutic effects.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsaberto-
Direitos: dc.rightsThis article is under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. Fonte: PDF do artigo.-
Título: dc.titleDevelopment and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.